Vaccine Strategy That Enhances the Protective Efficacy of Systemic Immunization by Establishing Lung-Resident Memory CD8 T Cells Against Influenza Infection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Most influenza vaccines currently in use target the highly variable hemagglutinin protein to induce neutralizing antibodies and therefore require yearly reformulation. T cell-based universal influenza vaccines focus on eliciting broadly cross-reactive T-cell responses, especially the tissue-resident memory T cell (TRM) population in the respiratory tract, providing superior protection to circulating memory T cells. This study demonstrated that intramuscular (i.m.) administration of the adenovirus-based vaccine expressing influenza virus nucleoprotein (rAd/NP) elicited weak CD8 TRM responses in the lungs and airways, and yielded poor protection against lethal influenza virus challenge. However, a novel “prime-and-deploy” strategy that combines i.m. vaccination of rAd/NP with subsequent intranasal administration of an empty adenovector induced strong NP-specific CD8+ TRM cells and provided complete protection against influenza virus challenge. Overall, our results demonstrate that this “prime-and-deploy” vaccination strategy is potentially applicable to the development of universal influenza vaccines.
Abstract
Most influenza vaccines currently in use target the highly variable hemagglutinin protein to induce neutralizing antibodies and therefore require yearly reformulation. T cell-based universal influenza vaccines focus on eliciting broadly cross-reactive T-cell responses, especially the tissue-resident memory T cell (TRM) population in the respiratory tract, providing superior protection to circulating memory T cells. This study demonstrated that intramuscular (i.m.) administration of the adenovirus-based vaccine expressing influenza virus nucleoprotein (rAd/NP) elicited weak CD8 TRM responses in the lungs and airways, and yielded poor protection against lethal influenza virus challenge. However, a novel “prime-and-deploy” strategy that combines i.m. vaccination of rAd/NP with subsequent intranasal administration of an empty adenovector induced strong NP-specific CD8+ TRM cells and provided complete protection against influenza virus challenge. Overall, our results demonstrate that this “prime-and-deploy” vaccination strategy is potentially applicable to the development of universal influenza vaccines.
참고문헌 (45)
- Flerlage T, "Influenza virus and SARS-CoV-2 : pathogenesis and host responses in the respiratory tract", Nat Rev Microbiol, 19, pp.425~441 (2021)
- Episcopio D, "Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus", FASEB J, 33, pp.9516~9525 (2019)
- Krammer F, "Influenza", Nat Rev Dis Primers, 4, pp.3~ (2018)
- Zambon MC, "Epidemiology and pathogenesis of influenza", J Antimicrob Chemother, 44(Suppl B), pp.3~9 (1999)
- Carrat F, "Influenza vaccine : the challenge of antigenic drift", Vaccine, 25, pp.6852~6862 (2007)
- Kim SK, "Private specificities of CD8 T cell responses control patterns of heterologous immunity", J Exp Med, 201, pp.523~533 (2005)
- Zheng M, "Development of universal influenza vaccines based on influenza virus M and NP genes", Infection, 42, pp.251~262 (2014)
- Ulmer JB, "Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA", J Virol, 72, pp.5648~5653 (1998)
- Flynn KJ, "Virus-specific CD8+ T cells in primary and secondary influenza pneumonia", Immunity, 8, pp.683~691 (1998)
- Townsend AR, "The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells", J Exp Med, 160, pp.552~563 (1984)
- 장준, "Adenovirus Vectors: Excellent Tools for Vaccine Development", Immune Network, 21(1), pp.1~11 (2021), 대한면역학회[DOI]
- Tatsis N, "Adenoviruses as vaccine vectors", Mol Ther, 10, pp.616~629 (2004)
- Kim SH, "Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection", PLoS One, 8, pp.e75460~ (2013)
- Lambe T, "Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1", Sci Rep, 3, pp.1443~ (2013)
- Price GE, "Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses", PLoS One, 5, pp.e13162~ (2010)
- Zhou D, "A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge", Mol Ther, 18, pp.2182~2189 (2010)
- Lund FE, "Scent of a vaccine", Science, 373, pp.397~399 (2021)
- Bevan MJ, "Memory T cells as an occupying force", Eur J Immunol, 41, pp.1192~1195 (2011)
- Schenkel JM, "Tissue-resident memory T cells", Immunity, 41, pp.886~897 (2014)
- Caminschi I, "Zymosan by-passes the requirement for pulmonary antigen encounter in lung tissue-resident memory CD8+ T cell development", Mucosal Immunol, 12, pp.403~412 (2019)
- Pizzolla A, "Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection", Sci Immunol, 2 (2017)
- Takamura S, "Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance", J Exp Med, 213, pp.3057~3073 (2016)
- Zens KD, "Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection", JCI Insight, 1, pp.e85832~ (2016)
- Zheng MZ, "Tissue resident memory T cells in the respiratory tract", Mucosal Immunol, 15, pp.379~388 (2022)
- Casey KA, "Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues", J Immunol, 188, pp.4866~4875 (2012)
- Wu T, "Lung-resident memory CD8 T cells(TRM)are indispensable for optimal cross-protection against pulmonary virus infection", J Leukoc Biol, 95, pp.215~224 (2014)
- Shin H, "A vaccine strategy that protects against genital herpes by establishing local memory T cells", Nature, 491, pp.463~467 (2012)
- 정햬린, "A “Prime and Deploy” Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T cells", Immune Network, 21(4), pp.1~14 (2021), 대한면역학회[DOI]
- Gupta N, "Determination of cutoff of ELISA and immunofluorescence assay for scrub typhus", J Glob Infect Dis, 8, pp.97~99 (2016)
- Brauer R, "Influenza virus propagation in embryonated chicken eggs", J Vis Exp, pp.52421~ (2015)
- Merten OW, "Production of influenza virus in cell cultures for vaccine preparation", Adv Exp Med Biol, 397, pp.141~151 (1996)
- Tobita K, "Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells(MDCK)in the presence of trypsin", Med Microbiol Immunol, 162, pp.9~14 (1975)
- Altman JD, "Phenotypic analysis of antigen-specific T lymphocytes", Science, 274, pp.94~96 (1996)
- Whelan JA, "Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent", J Immunol, 163, pp.4342~4348 (1999)
- Reber A, "Immunological assessment of influenza vaccines and immune correlates of protection", Expert Rev Vaccines, 12, pp.519~536 (2013)
- Nelson SA, Sant AJ, "Potentiating lung mucosal immunity through intranasal vaccination", 12, pp.808527~ (2021)
- Goldblatt D, "Correlates of protection against SARS-CoV-2 infection and COVID-19 disease", Immunol Rev, 310, pp.6~26 (2022)
- Bachmann MF, "Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells : T cell memory without"memory T cells"?", Proc Natl Acad Sci U S A, 94, pp.640~645 (1997)
- Bachmann MF, "Recall proliferation potential of memory CD8+ T cells and antiviral protection", J Immunol, 175, pp.4677~4685 (2005)
- Wherry EJ, "Lineage relationship and protective immunity of memory CD8 T cell subsets", Nat Immunol, 4, pp.225~234 (2003)
- Bull MB, "Next-generation T cell-activating vaccination increases influenza virus mutation prevalence", Sci Adv, 8 (2022)
- Mao T, "Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses", Science, 378 (2022)
- Mutsch M, "Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland", N Engl J Med, 350, pp.896~903 (2004)
- Tang J, "Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination", Sci Immunol, 7 (2022)
- Lapuente D, "Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization", Nat Commun, 12, pp.6871~ (2021)